Emerald Health Sciences Inc.

SEC source: 0001567619-23-005234 · doc1.xml · derivative · entry 7

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,500,000 shares

Expires 2024-03-29

F2 · kind: Aggregate exercise price for the warrants was paid through a reduction in the debt Issuer owed to Reporting Person under the Multi Draw Credit Facility.

SEC source: 0001567619-23-005234 · doc1.xml · derivative · entry 6

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,500,000 shares

Expires 2024-02-01

F2 · kind: Aggregate exercise price for the warrants was paid through a reduction in the debt Issuer owed to Reporting Person under the Multi Draw Credit Facility.

SEC source: 0001567619-23-005234 · doc1.xml · derivative · entry 5

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,500,000 shares

Expires 2023-11-01

SEC source: 0001567619-23-005234 · doc1.xml · derivative · entry 4

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,141,486 shares

Expires 2024-12-30

SEC source: 0001567619-23-005234 · doc1.xml · nonDerivative · entry 2

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 169,407,901

SEC source: 0001567619-23-005234 · doc1.xml · nonDerivative · entry 1

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 128,028,737

SEC source: 0001567619-23-005234 · doc1.xml · derivative · entry 3

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,141,486

Underlying: Common Stock · 9,141,486 shares

Expires 2024-12-30

F1 · kind: Warrants were acquired pursuant to a merger between Issuer and Emerald Health Therapeutics, Inc. ("Emerald"), whereby Reporting Person's outstanding warrants to purchase Emerald common stock were exchanged for warrants to purchase Issuer common stock.

SEC source: 0001640334-20-002029 · form4.xml · nonDerivative · entry 1

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 123,490,167

F1 · shares: Transfer of shares in a private transaction to directors, employees and consultants.

SEC source: 0001640334-20-002100 · form4a.xml · nonDerivative · entry 1

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 123,923,501

F1 · shares: The original Form 4, filed on August 11, 2020, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported a sale that occurred on August 7, 2020, as a total of 3,000,000 shares sold when in fact 2,566,6660 shares of the Issuer's common stock were sold. As a result of this administrative error, the number of shares beneficially owned by the reporting person following the corrected transaction reflects an addition in the number of shares reported as beneficially owned by the reporting person by 433,334 shares.

F1 · balance_after: The original Form 4, filed on August 11, 2020, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported a sale that occurred on August 7, 2020, as a total of 3,000,000 shares sold when in fact 2,566,6660 shares of the Issuer's common stock were sold. As a result of this administrative error, the number of shares beneficially owned by the reporting person following the corrected transaction reflects an addition in the number of shares reported as beneficially owned by the reporting person by 433,334 shares.

SEC source: 0001640334-22-000206 · form5.xml · nonDerivative · entry 1

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,387,251

F1 · kind: Transactions were previously reported on various prior Form 4 filings; however, the entries were erroneously reported as non-derivative transactions in Common Stock and the resulting reported total ownership included the misclassified securities. The entry of these transactions is to correct this error and reflect the actual securities held by the Reporting Person.

SEC source: 0001640334-22-000206 · form5.xml · derivative · entry 6

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,354,861

Underlying: Common Stock · 5,354,861 shares

Expires 2022-10-05

F1 · kind: Transactions were previously reported on various prior Form 4 filings; however, the entries were erroneously reported as non-derivative transactions in Common Stock and the resulting reported total ownership included the misclassified securities. The entry of these transactions is to correct this error and reflect the actual securities held by the Reporting Person.

F2 · derivative.expiration_date: The Multi Draw Credit Facility tranches have the option to convert into Common Stock upon maturity of the facilities.

SEC source: 0001640334-22-000206 · form5.xml · derivative · entry 4

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,500,000

Underlying: Common Stock · 2,500,000 shares

Expires 2024-03-29

F1 · kind: Transactions were previously reported on various prior Form 4 filings; however, the entries were erroneously reported as non-derivative transactions in Common Stock and the resulting reported total ownership included the misclassified securities. The entry of these transactions is to correct this error and reflect the actual securities held by the Reporting Person.

SEC source: 0001209191-19-006473 · doc4.xml · derivative · entry 2

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,500,000

Underlying: Common Stock · 2,500,000 shares

Expires not disclosed

F2 · kind: The common stock purchase warrant (the "Warrant") was issued to the reporting person in connection with the Advance pursuant to the Agreement. The Warrant is exercisable at the Reporting Person's option, in whole or in part, at any time after issuance. The expiration date is 5 years from the issuance of the Warrant. The Warrant shall continue to be exercisable notwithstanding the repayment in full of the Advance.

F3 · shares: Represents 50% of the number of shares issuable upon conversion of the Advance.

F2 · price: The common stock purchase warrant (the "Warrant") was issued to the reporting person in connection with the Advance pursuant to the Agreement. The Warrant is exercisable at the Reporting Person's option, in whole or in part, at any time after issuance. The expiration date is 5 years from the issuance of the Warrant. The Warrant shall continue to be exercisable notwithstanding the repayment in full of the Advance.

F2 · derivative.exercise_date: The common stock purchase warrant (the "Warrant") was issued to the reporting person in connection with the Advance pursuant to the Agreement. The Warrant is exercisable at the Reporting Person's option, in whole or in part, at any time after issuance. The expiration date is 5 years from the issuance of the Warrant. The Warrant shall continue to be exercisable notwithstanding the repayment in full of the Advance.

F2 · derivative.expiration_date: The common stock purchase warrant (the "Warrant") was issued to the reporting person in connection with the Advance pursuant to the Agreement. The Warrant is exercisable at the Reporting Person's option, in whole or in part, at any time after issuance. The expiration date is 5 years from the issuance of the Warrant. The Warrant shall continue to be exercisable notwithstanding the repayment in full of the Advance.

SEC source: 0001209191-19-006473 · doc4.xml · derivative · entry 1

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: Not disclosed

Underlying: Common Stock · 5,000,000 shares

Expires not disclosed

F1 · kind: Represents an advance of $2,000,000 (the "Advance") made by the Reporting Person to the Issuer pursuant to a Multi-Draw Credit Agreement, between the Issuer and the Reporting Person (the "Agreement"). The Advance is convertible into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), at the Reporting Person's option, in whole or in part, at any time after issuance. The conversion price of $.40 per share of Common Stock will be subject to adjustment for stock dividends, stock splits, dilutive securities issuances and other customary adjustment events. The maturity date is the earlier of (a) October 5, 2022 and (b) the date on which all amounts under the Agreement shall become due and payable.

F1 · price: Represents an advance of $2,000,000 (the "Advance") made by the Reporting Person to the Issuer pursuant to a Multi-Draw Credit Agreement, between the Issuer and the Reporting Person (the "Agreement"). The Advance is convertible into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), at the Reporting Person's option, in whole or in part, at any time after issuance. The conversion price of $.40 per share of Common Stock will be subject to adjustment for stock dividends, stock splits, dilutive securities issuances and other customary adjustment events. The maturity date is the earlier of (a) October 5, 2022 and (b) the date on which all amounts under the Agreement shall become due and payable.

F1 · derivative.exercise_date: Represents an advance of $2,000,000 (the "Advance") made by the Reporting Person to the Issuer pursuant to a Multi-Draw Credit Agreement, between the Issuer and the Reporting Person (the "Agreement"). The Advance is convertible into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), at the Reporting Person's option, in whole or in part, at any time after issuance. The conversion price of $.40 per share of Common Stock will be subject to adjustment for stock dividends, stock splits, dilutive securities issuances and other customary adjustment events. The maturity date is the earlier of (a) October 5, 2022 and (b) the date on which all amounts under the Agreement shall become due and payable.

F1 · derivative.expiration_date: Represents an advance of $2,000,000 (the "Advance") made by the Reporting Person to the Issuer pursuant to a Multi-Draw Credit Agreement, between the Issuer and the Reporting Person (the "Agreement"). The Advance is convertible into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), at the Reporting Person's option, in whole or in part, at any time after issuance. The conversion price of $.40 per share of Common Stock will be subject to adjustment for stock dividends, stock splits, dilutive securities issuances and other customary adjustment events. The maturity date is the earlier of (a) October 5, 2022 and (b) the date on which all amounts under the Agreement shall become due and payable.

SEC source: 0001640334-22-000206 · form5.xml · derivative · entry 5

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,822

Underlying: Common Stock · 38,822 shares

Expires 2022-10-05

F1 · kind: Transactions were previously reported on various prior Form 4 filings; however, the entries were erroneously reported as non-derivative transactions in Common Stock and the resulting reported total ownership included the misclassified securities. The entry of these transactions is to correct this error and reflect the actual securities held by the Reporting Person.

F2 · derivative.expiration_date: The Multi Draw Credit Facility tranches have the option to convert into Common Stock upon maturity of the facilities.

SEC source: 0001640334-22-000206 · form5.xml · derivative · entry 3

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,500,000

Underlying: Common Stock · 2,500,000 shares

Expires 2024-02-01

F1 · kind: Transactions were previously reported on various prior Form 4 filings; however, the entries were erroneously reported as non-derivative transactions in Common Stock and the resulting reported total ownership included the misclassified securities. The entry of these transactions is to correct this error and reflect the actual securities held by the Reporting Person.

SEC source: 0001209191-18-064353 · doc4.xml · nonDerivative · entry 1

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,153,917

F1 · kind: The shares were issued pursuant to the conversion of accrued and unpaid interest on a convertible note, which is no longer outstanding, at the conversion price of $.10 per share.

F1 · price: The shares were issued pursuant to the conversion of accrued and unpaid interest on a convertible note, which is no longer outstanding, at the conversion price of $.10 per share.

SEC source: 0001209191-18-056825 · doc4.xml · derivative · entry 2

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,500,000

Underlying: Common Stock · 2,500,000 shares

Expires not disclosed

F2 · kind: The common stock purchase warrant (the "Warrant") was issued to the reporting person in connection with the Advance pursuant to the Agreement. The Warrant is exercisable at the Reporting Person's option, in whole or in part, at any time after issuance. The expiration date is 5 years from the issuance of the Warrant. The Warrant shall continue to be exercisable notwithstanding the repayment in full of the Advance.

F3 · shares: Represents 50% of the number of shares issuable upon conversion of the Advance.

F2 · price: The common stock purchase warrant (the "Warrant") was issued to the reporting person in connection with the Advance pursuant to the Agreement. The Warrant is exercisable at the Reporting Person's option, in whole or in part, at any time after issuance. The expiration date is 5 years from the issuance of the Warrant. The Warrant shall continue to be exercisable notwithstanding the repayment in full of the Advance.

F2 · derivative.exercise_date: The common stock purchase warrant (the "Warrant") was issued to the reporting person in connection with the Advance pursuant to the Agreement. The Warrant is exercisable at the Reporting Person's option, in whole or in part, at any time after issuance. The expiration date is 5 years from the issuance of the Warrant. The Warrant shall continue to be exercisable notwithstanding the repayment in full of the Advance.

F2 · derivative.expiration_date: The common stock purchase warrant (the "Warrant") was issued to the reporting person in connection with the Advance pursuant to the Agreement. The Warrant is exercisable at the Reporting Person's option, in whole or in part, at any time after issuance. The expiration date is 5 years from the issuance of the Warrant. The Warrant shall continue to be exercisable notwithstanding the repayment in full of the Advance.

SEC source: 0001209191-18-056825 · doc4.xml · derivative · entry 1

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: Not disclosed

Underlying: Common Stock · 5,000,000 shares

Expires not disclosed

F1 · kind: Represents an advance of $2,000,000 (the "Advance") made by the Reporting Person to the Issuer pursuant to a Multi-Draw Credit Agreement, between the Issuer and the Reporting Person (the "Agreement"). The Advance is convertible into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), at the Reporting Person's option, in whole or in part, at any time after issuance. The conversion price of $.40 per share of Common Stock will be subject to adjustment for stock dividends, stock splits, dilutive securities issuances and other customary adjustment events. The maturity date is the earlier of (a) October 5, 2022 and (b) the date on which all amounts under the Agreement shall become due and payable.

F1 · price: Represents an advance of $2,000,000 (the "Advance") made by the Reporting Person to the Issuer pursuant to a Multi-Draw Credit Agreement, between the Issuer and the Reporting Person (the "Agreement"). The Advance is convertible into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), at the Reporting Person's option, in whole or in part, at any time after issuance. The conversion price of $.40 per share of Common Stock will be subject to adjustment for stock dividends, stock splits, dilutive securities issuances and other customary adjustment events. The maturity date is the earlier of (a) October 5, 2022 and (b) the date on which all amounts under the Agreement shall become due and payable.

F1 · derivative.exercise_date: Represents an advance of $2,000,000 (the "Advance") made by the Reporting Person to the Issuer pursuant to a Multi-Draw Credit Agreement, between the Issuer and the Reporting Person (the "Agreement"). The Advance is convertible into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), at the Reporting Person's option, in whole or in part, at any time after issuance. The conversion price of $.40 per share of Common Stock will be subject to adjustment for stock dividends, stock splits, dilutive securities issuances and other customary adjustment events. The maturity date is the earlier of (a) October 5, 2022 and (b) the date on which all amounts under the Agreement shall become due and payable.

F1 · derivative.expiration_date: Represents an advance of $2,000,000 (the "Advance") made by the Reporting Person to the Issuer pursuant to a Multi-Draw Credit Agreement, between the Issuer and the Reporting Person (the "Agreement"). The Advance is convertible into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), at the Reporting Person's option, in whole or in part, at any time after issuance. The conversion price of $.40 per share of Common Stock will be subject to adjustment for stock dividends, stock splits, dilutive securities issuances and other customary adjustment events. The maturity date is the earlier of (a) October 5, 2022 and (b) the date on which all amounts under the Agreement shall become due and payable.

SEC source: 0001640334-22-000206 · form5.xml · derivative · entry 2

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,500,000

Underlying: Common Stock · 2,500,000 shares

Expires 2023-11-01

F1 · kind: Transactions were previously reported on various prior Form 4 filings; however, the entries were erroneously reported as non-derivative transactions in Common Stock and the resulting reported total ownership included the misclassified securities. The entry of these transactions is to correct this error and reflect the actual securities held by the Reporting Person.

SEC source: 0001209191-18-023388 · doc4.xml · derivative · entry 4

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,000,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The Series F Convertible Preferred Stock is convertible at any time, at the holder's election, and has no expiration date.

F2 · derivative.expiration_date: The Series F Convertible Preferred Stock is convertible at any time, at the holder's election, and has no expiration date.

SEC source: 0001209191-18-023388 · doc4.xml · derivative · entry 3

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,335,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The Series B Convertible Preferred Stock is convertible at any time, at the holder's election, and has no expiration date.

F1 · derivative.expiration_date: The Series B Convertible Preferred Stock is convertible at any time, at the holder's election, and has no expiration date.

SEC source: 0001209191-18-023388 · doc4.xml · nonDerivative · entry 2

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,116,250

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-18-023388 · doc4.xml · nonDerivative · entry 1

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,116,250

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-18-011938 · doc4.xml · derivative · entry 2

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,400,000

Underlying: Common Stock · 20,400,000 shares

Expires 2023-02-16

F1 · kind: The reporting person purchased in a private placement 15,000,000 shares (the "Shares") of the Issuer's common stock, par value $0.001 per share (the "Common Stock"), and a warrant (the "Warrant") to purchase 20,400,000 shares of Common Stock at an exercise price of $0.10 per share. The Shares and the Warrant were purchased as a unit at $.10 per unit.

F1 · price: The reporting person purchased in a private placement 15,000,000 shares (the "Shares") of the Issuer's common stock, par value $0.001 per share (the "Common Stock"), and a warrant (the "Warrant") to purchase 20,400,000 shares of Common Stock at an exercise price of $0.10 per share. The Shares and the Warrant were purchased as a unit at $.10 per unit.

SEC source: 0001209191-18-011938 · doc4.xml · nonDerivative · entry 1

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,000,000

F1 · kind: The reporting person purchased in a private placement 15,000,000 shares (the "Shares") of the Issuer's common stock, par value $0.001 per share (the "Common Stock"), and a warrant (the "Warrant") to purchase 20,400,000 shares of Common Stock at an exercise price of $0.10 per share. The Shares and the Warrant were purchased as a unit at $.10 per unit.

F1 · price: The reporting person purchased in a private placement 15,000,000 shares (the "Shares") of the Issuer's common stock, par value $0.001 per share (the "Common Stock"), and a warrant (the "Warrant") to purchase 20,400,000 shares of Common Stock at an exercise price of $0.10 per share. The Shares and the Warrant were purchased as a unit at $.10 per unit.

SEC source: 0001209191-18-016047 · doc4.xml · derivative · entry 2

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,781,250 shares

Expires 2020-08-20

SEC source: 0001209191-18-016047 · doc4.xml · nonDerivative · entry 1

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,781,250